资讯

Applied Clinical Trials Online3 小时
How Sites and Sponsors Are Adapting to Clinical Trial Budget Cuts
In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how clinical trial sites and sponsors are ...
Applied Clinical Trials Online18 小时
How Funding Cuts Are Undermining Patient Recruitment in Clinical Trials
In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how staffing reductions caused by clinical trial ...
Applied Clinical Trials Online23 小时
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.